{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:43:06Z","timestamp":1785328986081,"version":"3.55.0"},"reference-count":155,"publisher":"Elsevier","isbn-type":[{"value":"9780128246160","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.acc.2020.08.007","type":"book-chapter","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T10:19:15Z","timestamp":1603189155000},"page":"97-134","source":"Crossref","is-referenced-by-count":22,"title":["Synuclein in neurodegeneration"],"prefix":"10.1016","member":"78","reference":[{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1474-4422(19)30029-8","article-title":"The global burden of neurological disorders","volume":"18","author":"Carroll","year":"2019","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/diagnostics10050339","article-title":"Parkinson's disease: available clinical and promising omics tests for diagnostics, disease risk assessment, and pharmacotherapy personalization","volume":"10","author":"Trifonova","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-3-1-reviews3002","article-title":"The synucleins","volume":"3","author":"George","year":"2002","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1212\/CON.0000000000000819","article-title":"Synucleinopathies","volume":"26","author":"Coon","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.acc.2020.08.007_bb0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","article-title":"Targeting alpha-synuclein as a therapy for Parkinson's disease","volume":"12","author":"Fields","year":"2019","journal-title":"Front. Mol. Neurosci."},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.semnuclmed.2018.07.006","article-title":"PET imaging in movement disorders","volume":"48","author":"Maiti","year":"2018","journal-title":"Semin. Nucl. Med."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0045","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: a systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"40","author":"Bougea","year":"2019","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0055","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/mds.26547","article-title":"Imaging synucleinopathies","volume":"31","author":"Brooks","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.acc.2020.08.007_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2015.05.004","article-title":"Fluid biomarkers in multiple system atrophy: a review of the MSA biomarker initiative","volume":"80","author":"Laurens","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11910-019-0918-y","article-title":"CSF biomarkers for early diagnosis of synucleinopathies: focus on idiopathic RBD","volume":"19","author":"Liguori","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"11","key":"10.1016\/bs.acc.2020.08.007_bb0120","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00702-019-02062-4","article-title":"Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review","volume":"126","author":"Bougea","year":"2019","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175674","article-title":"Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease","volume":"12","author":"Caspell-Garcia","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0065","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early Parkinson's Disease: Parkinson's progression markers initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0070","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ana.22284","article-title":"Age-specific progression of nigrostriatal dysfunction in Parkinson's disease","volume":"69","author":"de la Fuente-Fernandez","year":"2011","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0075","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2967\/jnumed.111.089946","article-title":"Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study","volume":"52","author":"Bohnen","year":"2011","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3233\/JPD-150583","article-title":"Hypometabolism in posterior and temporal areas of the brain is associated with cognitive decline in Parkinson's disease","volume":"5","author":"Tard","year":"2015","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0085","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2016-313918","article-title":"Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study","volume":"88","author":"Firbank","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/bs.acc.2020.08.007_bb0090","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jns.2016.11.068","article-title":"Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease","volume":"372","author":"Baba","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"Pt. 7","key":"10.1016\/bs.acc.2020.08.007_bb0095","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/awm086","article-title":"Changes in network activity with the progression of Parkinson's disease","volume":"130","author":"Huang","year":"2007","journal-title":"Brain"},{"issue":"11","key":"10.1016\/bs.acc.2020.08.007_bb0100","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/jnnp-2017-317398","article-title":"(123)I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study","volume":"89","author":"Komatsu","year":"2018","journal-title":"J. Neurol. Neurochir. Psychiatr."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0105","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1468-1331.2011.03392.x","article-title":"Follow-up study of cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder","volume":"18","author":"Miyamoto","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/bs.acc.2020.08.007_bb0125","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","article-title":"Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal","volume":"8","author":"Maroteaux","year":"1988","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/MN:30:1:001","article-title":"Neurobiology of alpha-synuclein","volume":"30","author":"Vekrellis","year":"2004","journal-title":"Mol. Neurobiol."},{"issue":"5999","key":"10.1016\/bs.acc.2020.08.007_bb0135","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Burr\u00e9","year":"2010","journal-title":"Science"},{"key":"10.1016\/bs.acc.2020.08.007_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fnins.2018.00080","article-title":"Mechanisms of \u03b1-synuclein induced synaptopathy in Parkinson's disease","volume":"12","author":"Bridi","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/bs.acc.2020.08.007_bb0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.pbr.2019.10.005","article-title":"Mechanisms of alpha-synuclein toxicity: an update and outlook","volume":"252","author":"Br\u00e1s","year":"2020","journal-title":"Prog. Brain Res."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016706","article-title":"Resistance to MPTP-neurotoxicity in \u03b1-synuclein knockout mice is complemented by human \u03b1-synuclein and associated with increased \u03b2-synuclein and Akt activation","volume":"6","author":"Thomas","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/exnr.2000.7615","article-title":"Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra","volume":"168","author":"Galvin","year":"2001","journal-title":"Exp. Neurol."},{"issue":"20","key":"10.1016\/bs.acc.2020.08.007_bb0160","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1523\/JNEUROSCI.6194-10.2011","article-title":"Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family","volume":"31","author":"Anwar","year":"2011","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0170","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0165","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2009.06.017","article-title":"Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology","volume":"36","author":"Drolet","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0175","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12031-016-0829-1","article-title":"Interactions between alpha-synuclein and tau protein: implications to neurodegenerative disorders","volume":"60","author":"Li","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/bs.acc.2020.08.007_bb0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1326-5-47","article-title":"Parkinson-related parkin reduces alpha-synuclein phosphorylation in a gene transfer model","volume":"5","author":"Khandelwal","year":"2010","journal-title":"Mol. Neurodegener."},{"issue":"12","key":"10.1016\/bs.acc.2020.08.007_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029257","article-title":"Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease","volume":"6","author":"Morris","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/bs.acc.2020.08.007_bb0190","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/nn.4648","article-title":"\u03b1-Synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B","volume":"20","author":"Ferreira","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"5012","key":"10.1016\/bs.acc.2020.08.007_bb0195","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1675487","article-title":"Molecular biology of prion diseases","volume":"252","author":"Prusiner","year":"1991","journal-title":"Science"},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0200","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0205","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/jnc.14779","article-title":"Spreading of alpha-synuclein\u2014relevant or epiphenomenon?","volume":"150","author":"Killinger","year":"2019","journal-title":"J. Neurochem."},{"issue":"38","key":"10.1016\/bs.acc.2020.08.007_bb0210","doi-asserted-by":"crossref","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","article-title":"Evidence for \u03b1-synuclein prions causing multiple system atrophy in humans with parkinsonism","volume":"112","author":"Prusiner","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00441-017-2712-y","article-title":"A critical review of the prion hypothesis of human synucleinopathies","volume":"373","author":"Tamg\u00fcney","year":"2018","journal-title":"Cell Tissue Res."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0220","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/bs.acc.2020.08.007_bb0225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fnmol.2019.00107","article-title":"Spreading of \u03b1-synuclein and tau: a systematic comparison of the mechanisms involved","volume":"12","author":"Vasili","year":"2019","journal-title":"Front. Mol. Neurosci."},{"issue":"11","key":"10.1016\/bs.acc.2020.08.007_bb0230","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00401-004-0935-y","article-title":"The role of alpha-synuclein in the pathogenesis of multiple system atrophy","volume":"109","author":"Wenning","year":"2005","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0240","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/cells8060565","article-title":"Autophagy in synucleinopathy: the overwhelmed and defective machinery","volume":"8","author":"Arotcarena","year":"2019","journal-title":"Cell"},{"issue":"5321","key":"10.1016\/bs.acc.2020.08.007_bb0245","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0250","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","article-title":"Alpha-synuclein oligomers: a new hope","volume":"134","author":"Bengoa-Vergniory","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0255","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","article-title":"Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein","volume":"34","author":"Giasson","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/bs.acc.2020.08.007_bb0260","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fnana.2014.00155","article-title":"Parkinson's disease: animal models and dopaminergic cell vulnerability","volume":"8","author":"Blesa","year":"2014","journal-title":"Front. Neuroanat."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/BMM.14.105","article-title":"The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature","volume":"10","author":"Simonsen","year":"2016","journal-title":"Biomark. Med."},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0270","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson's disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/bs.acc.2020.08.007_bb0275","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/bs.acc.2020.08.007_bb0280","first-page":"567386","article-title":"The diagnostic and differential diagnosis utility of cerebrospinal fluid alpha -synuclein levels in Parkinson's disease: a meta-analysis","volume":"2015","author":"Zhou","year":"2015","journal-title":"Parkinsons Dis."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0290","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ajpath.2013.12.007","article-title":"Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort","volume":"184","author":"Stewart","year":"2014","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/bs.acc.2020.08.007_bb0295","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/mds.27806","article-title":"Longitudinal analyses of cerebrospinal fluid alpha-synuclein in prodromal and early Parkinson's disease","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.acc.2020.08.007_bb0300","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.parkreldis.2018.01.018","article-title":"Evolution of cerebrospinal fluid total alpha-synuclein in Parkinson's disease","volume":"49","author":"Forland","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0305","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/mds.26754","article-title":"Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression","volume":"31","author":"Majbour","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.acc.2020.08.007_bb0310","doi-asserted-by":"crossref","first-page":"40263","DOI":"10.1038\/srep40263","article-title":"Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease","volume":"7","author":"Majbour","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0315","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00415-014-7334-7","article-title":"Increased alpha-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"261","author":"Kasai","year":"2014","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0320","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mds.26656","article-title":"Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-from pathophysiology to clinical practice","volume":"31","author":"Blennow","year":"2016","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0325","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3233\/JAD-141287","article-title":"Cerebrospinal fluid alpha-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease","volume":"43","author":"Mackin","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0330","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/bs.acc.2020.08.007_bb0335","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/bs.acc.2020.08.007_bb0705","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1096\/fj.10-179192","article-title":"Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease","volume":"25","author":"Foulds","year":"2011","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0715","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/bs.acc.2020.08.007_bb0720","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2018.01.025","article-title":"Identification of a prospective early motor progression cluster of Parkinson's disease: data from the PPMI study","volume":"387","author":"Vavougios","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/bs.acc.2020.08.007_bb0710","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/mds.27775","article-title":"Evolution and clustering of prodromal parkinsonian features in GBA1 carriers","volume":"34","author":"Mullin","year":"2019","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/bs.acc.2020.08.007_bb0725","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4103\/1947-2714.147980","article-title":"Saliva alpha-synuclein and a high extinction coefficient protein: a novel approach in assessment biomarkers of Parkinson's disease","volume":"6","author":"Al-Nimer","year":"2014","journal-title":"N. Am. J. Med. Sci."},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151156","article-title":"Abnormal salivary total and oligomeric alpha-synuclein in Parkinson's disease","volume":"11","author":"Vivacqua","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.08.007_bb0735","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.parkreldis.2019.02.014","article-title":"Salivary alpha-synuclein in the diagnosis of Parkinson's disease and progressive supranuclear palsy","volume":"63","author":"Vivacqua","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/bs.acc.2020.08.007_bb0740","doi-asserted-by":"crossref","first-page":"28143","DOI":"10.1038\/srep28143","article-title":"Salivary total alpha-synuclein, oligomeric alpha-synuclein and SNCA variants in Parkinson's disease patients","volume":"6","author":"Kang","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0745","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/mds.27232","article-title":"Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and Parkinson's disease features","volume":"33","author":"Goldman","year":"2018","journal-title":"Mov. Disord."},{"issue":"Pt. 7","key":"10.1016\/bs.acc.2020.08.007_bb0750","article-title":"Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease","volume":"134","author":"Devic","year":"2011","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0755","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.neurobiolaging.2013.08.008","article-title":"Cheek cell-derived alpha-synuclein and DJ-1 do not differentiate Parkinson's disease from control","volume":"35","author":"Stewart","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/bs.acc.2020.08.007_bb0760","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neulet.2018.12.030","article-title":"Alpha-synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease","volume":"696","author":"Cao","year":"2018","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0765","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer's disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0770","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mds.23795","article-title":"Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts","volume":"27","author":"Jellinger","year":"2012","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/bs.acc.2020.08.007_bb0775","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1074\/jbc.M110.178905","article-title":"Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro","volume":"286","author":"Qureshi","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0780","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.expneurol.2004.01.007","article-title":"Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation","volume":"187","author":"Kotzbauer","year":"2004","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0340","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0345","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00702-019-02137-2","article-title":"High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases","volume":"127","author":"Bougea","year":"2020","journal-title":"J. Neural. Transm. (Vienna)"},{"issue":"11","key":"10.1016\/bs.acc.2020.08.007_bb0355","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.111","article-title":"Alpha-synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies","volume":"33","author":"van Steenoven","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.acc.2020.08.007_bb0350","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cca.2018.11.027","article-title":"Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies","volume":"490","author":"Bousiges","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2020.08.007_bb0360","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fneur.2018.00415","article-title":"Are we ready for detecting \u03b1-synuclein prone to aggregation in patients? The case of \"protein-misfolding cyclic amplification\" and \"real-time quaking-induced conversion\" as diagnostic tools","volume":"9","author":"Paciotti","year":"2018","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0365","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"Pt. 2","key":"10.1016\/bs.acc.2020.08.007_bb0370","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/brain\/awv346","article-title":"Induction of \u03b1-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies","volume":"139","author":"Stuendl","year":"2016","journal-title":"Brain"},{"key":"10.1016\/bs.acc.2020.08.007_bb0375","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2019.05.002","article-title":"Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification","volume":"129","author":"Fenyi","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0380","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1212\/WNL.0000000000004146","article-title":"A new potential biomarker for dementia with Lewy bodies: skin nerve \u03b1-synuclein deposits","volume":"89","author":"Donadio","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0385","doi-asserted-by":"crossref","first-page":"14246","DOI":"10.1038\/s41598-018-32588-8","article-title":"Skin \u03b1-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study","volume":"8","author":"Donadio","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/bs.acc.2020.08.007_bb0390","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0395","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/nan.12362","article-title":"Progression of alpha-synuclein pathology in multiple system atrophy of the cerebellar type","volume":"43","author":"Brettschneider","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"11","key":"10.1016\/bs.acc.2020.08.007_bb0400","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0405","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00415-014-7568-4","article-title":"Ancillary investigations to diagnose parkinsonism: a prospective clinical study","volume":"262","author":"Aerts","year":"2015","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136575","article-title":"Involvement of peripheral nerves in the transgenic PLP-\u03b1-Syn model of multiple system atrophy: extending the phenotype","volume":"10","author":"Kuzdas-Wood","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.08.007_bb0415","first-page":"167038","article-title":"Clinical utility of skin biopsy in differentiating between Parkinson's disease and multiple system atrophy","volume":"2015","author":"Haga","year":"2015","journal-title":"Parkinsons Dis."},{"issue":"12","key":"10.1016\/bs.acc.2020.08.007_bb0420","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/mds.26293","article-title":"Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy","volume":"30","author":"Doppler","year":"2015","journal-title":"Mov. Disord."},{"issue":"24","key":"10.1016\/bs.acc.2020.08.007_bb0425","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1212\/WNL.0000000000000518","article-title":"Postganglionic sudomotor denervation in patients with multiple system atrophy","volume":"82","author":"Provitera","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0430","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.nbd.2012.07.018","article-title":"Expression pattern and localization of alpha-synuclein in the human enteric nervous system","volume":"48","author":"B\u00f6ttner","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/bs.acc.2020.08.007_bb0435","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fneur.2019.00363","article-title":"Autonomic dysfunction in \u03b1-synucleinopathies","volume":"10","author":"Mendoza-Vel\u00e1squez","year":"2019","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0440","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.24877","article-title":"Natural history of pure autonomic failure: a United States prospective cohort","volume":"81","author":"Kaufmann","year":"2017","journal-title":"Ann. Neurol."},{"issue":"3062","key":"10.1016\/bs.acc.2020.08.007_bb0445","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.118.3062.273","article-title":"Regularly occurring periods of eye motility, and concomitant phenomena, during sleep","volume":"118","author":"Aserinsky","year":"1953","journal-title":"Science"},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0450","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.parkreldis.2013.02.009","article-title":"Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder","volume":"19","author":"Iranzo","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"issue":"8","key":"10.1016\/bs.acc.2020.08.007_bb0455","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/jnnp-2015-311437","article-title":"Progression of cognitive impairments in idiopathic REM sleep behaviour disorder","volume":"87","author":"Youn","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0460","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(16)00057-0","article-title":"Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions","volume":"15","author":"Iranzo","year":"2016","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0465","first-page":"619","article-title":"Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder","volume":"34","author":"Fantini","year":"2011","journal-title":"Sleep"},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0470","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.5665\/sleep.3050","article-title":"Cognitive performances and mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder: results of a longitudinal follow-up study","volume":"36","author":"Terzaghi","year":"2013","journal-title":"Sleep"},{"key":"10.1016\/bs.acc.2020.08.007_bb0475","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3389\/fneur.2018.00560","article-title":"Longitudinal alterations of alpha-synuclein, amyloid beta, total, and phosphorylated tau in cerebrospinal fluid and correlations between their changes in Parkinson's disease","volume":"9","author":"Dolatshahi","year":"2018","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0480","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1212\/WNL.0000000000006134","article-title":"REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease","volume":"91","author":"Pagano","year":"2018","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/bs.acc.2020.08.007_bb0485","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1212\/WNL.0000000000003989","article-title":"Skin nerve phosphorylated \u03b1-synuclein deposits in idiopathic REM sleep behavior disorder","volume":"88","author":"Antelmi","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0490","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archneur.1974.00490310072012","article-title":"Hallervorden-Spatz syndrome","volume":"30","author":"Dooling","year":"1974","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14802\/jmd.14034","article-title":"Neurodegeneration with brain iron accumulation: diagnosis and management","volume":"8","author":"Hogarth","year":"2015","journal-title":"J. Mov. Disord."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0500","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0002-9440(10)64548-8","article-title":"Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology","volume":"157","author":"Galvin","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.acc.2020.08.007_bb0505","first-page":"132","article-title":"New \u03b1- and \u03b3-synuclein immunopathological lesions in human brain","volume":"2","author":"Surgucheva","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"Suppl. 2","key":"10.1016\/bs.acc.2020.08.007_bb0510","doi-asserted-by":"crossref","first-page":"Ii19","DOI":"10.1007\/BF03161078","article-title":"Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: an update","volume":"246","author":"Oyanagi","year":"1999","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0515","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0002-9440(10)61119-4","article-title":"Tau and alpha-synuclein pathology in amygdala of parkinsonism-dementia complex patients of Guam","volume":"160","author":"Forman","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0520","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4","article-title":"Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease","volume":"45","author":"Lippa","year":"1999","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0525","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/NEN.0b013e318196e905","article-title":"Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions","volume":"68","author":"Lu","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0530","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.mcn.2006.01.007","article-title":"Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease","volume":"31","author":"Papadopoulos","year":"2006","journal-title":"Mol. Cell. Neurosci."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0535","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0037-1601567","article-title":"Genetic forms of Parkinson's disease","volume":"37","author":"Kim","year":"2017","journal-title":"Semin. Neurol."},{"issue":"8","key":"10.1016\/bs.acc.2020.08.007_bb0540","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/mds.26615","article-title":"Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a longitudinal study","volume":"31","author":"Papadimitriou","year":"2016","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/bs.acc.2020.08.007_bb0545","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.parkreldis.2015.10.008","article-title":"Neurodegenerative CSF markers in genetic and sporadic PD: classification and prediction in a longitudinal study","volume":"21","author":"Brockmann","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0550","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov. Disord."},{"issue":"Pt. 2","key":"10.1016\/bs.acc.2020.08.007_bb0555","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/brain\/aws318","article-title":"Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort","volume":"136","author":"Winder-Rhodes","year":"2013","journal-title":"Brain"},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0560","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/bs.acc.2020.08.007_bb0565","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's","volume":"80","author":"Liu","year":"2016","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0570","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000348","article-title":"Genetic risk of Parkinson disease and progression: an analysis of 13 longitudinal cohorts","volume":"5","author":"Iwaki","year":"2019","journal-title":"Neurol. Genet."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0575","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.220","article-title":"Exome sequencing in dementia with Lewy bodies","volume":"6","author":"Keogh","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0580","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/bs.acc.2020.08.007_bb0585","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13024-015-0038-3","article-title":"Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation","volume":"10","author":"Kiely","year":"2015","journal-title":"Mol. Neurodegener."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2011.04.001","article-title":"Genetic players in multiple system atrophy: unfolding the nature of the beast","volume":"32","author":"Stemberger","year":"2011","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0595","first-page":"433","article-title":"PET\/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases","volume":"5","author":"Lu","year":"2015","journal-title":"Quant. Imaging Med. Surg."},{"issue":"1\u20133","key":"10.1016\/bs.acc.2020.08.007_bb0600","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","article-title":"In vitro characterisation of BF227 binding to alpha-synuclein\/Lewy bodies","volume":"617","author":"Fodero-Tavoletti","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"Pt. 6","key":"10.1016\/bs.acc.2020.08.007_bb0605","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/brain\/awq091","article-title":"In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy","volume":"133","author":"Kikuchi","year":"2010","journal-title":"Brain"},{"issue":"Pt. 8","key":"10.1016\/bs.acc.2020.08.007_bb0060","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/brain\/aww124","article-title":"Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's disease","volume":"139","author":"Rolinski","year":"2016","journal-title":"Brain"},{"issue":"8","key":"10.1016\/bs.acc.2020.08.007_bb0610","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/brain\/awx146","article-title":"Progression marker of Parkinson's disease: a 4-year multi-site imaging study","volume":"140","author":"Burciu","year":"2017","journal-title":"Brain"},{"issue":"22","key":"10.1016\/bs.acc.2020.08.007_bb0615","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1212\/01.wnl.0000335973.66333.58","article-title":"Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study","volume":"71","author":"Nandhagopal","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0620","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1212\/WNL.0000000000004201","article-title":"Loss of phosphodiesterase 4 in Parkinson disease: relevance to cognitive deficits","volume":"89","author":"Niccolini","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.acc.2020.08.007_bb0625","first-page":"378","article-title":"Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET","volume":"36","author":"Eidelberg","year":"1995","journal-title":"J. Nucl. Med."},{"issue":"Pt. 10","key":"10.1016\/bs.acc.2020.08.007_bb0630","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/brain\/awl162","article-title":"Network modulation in the treatment of Parkinson's disease","volume":"129","author":"Asanuma","year":"2006","journal-title":"Brain"},{"issue":"6","key":"10.1016\/bs.acc.2020.08.007_bb0635","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.parkreldis.2012.04.017","article-title":"Meta-analysis on MIBG scintigraphy in differential diagnosis between Parkinson's disease and neurodegenerative parkinsonism","volume":"18","author":"Treglia","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"2","key":"10.1016\/bs.acc.2020.08.007_bb0640","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/jnnp.2004.037028","article-title":"Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease","volume":"76","author":"Nagayama","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0645","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/RLU.0000000000002424","article-title":"Initial versus follow-up sequential myocardial 123I-MIBG scintigraphy to discriminate Parkinson disease from atypical parkinsonian syndromes","volume":"44","author":"Ryu","year":"2019","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0650","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mdc3.12697","article-title":"MIBG myocardial scintigraphy identifies premotor PD\/DLB during a negative DAT scan period: second report","volume":"6","author":"Sakakibara","year":"2019","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"4","key":"10.1016\/bs.acc.2020.08.007_bb0655","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.parkreldis.2009.12.010","article-title":"Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease","volume":"16","author":"Kashihara","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0660","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","article-title":"Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease","volume":"72","author":"Backstrom","year":"2015","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/bs.acc.2020.08.007_bb0665","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/mds.27136","article-title":"Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Parkinson's disease patients","volume":"32","author":"Parnetti","year":"2017","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/bs.acc.2020.08.007_bb0670","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/mds.25772","article-title":"Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease","volume":"29","author":"Parnetti","year":"2014","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0675","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/bs.acc.2020.08.007_bb0685","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2013.03.009","article-title":"Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study","volume":"19","author":"Compta","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"issue":"7","key":"10.1016\/bs.acc.2020.08.007_bb0690","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.acc.2020.08.007_bb0695","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41598-018-37545-z","article-title":"Data-driven subtyping of Parkinson's disease using longitudinal clinical records: a cohort study","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/bs.acc.2020.08.007_bb0700","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1474-4422(17)30328-9","article-title":"Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation","volume":"16","author":"Latourelle","year":"2017","journal-title":"Lancet Neurol."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242320300962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242320300962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:40:21Z","timestamp":1758742821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242320300962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780128246160"],"references-count":155,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2020.08.007","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}